ADC Therapeutics, a late clinical-stage oncology-focused biotechnology, and Overland Pharmaceuticals, a fully integrated biopharmaceutical company, agreed to form Overland ADCT BioPharma. Financial terms were not disclosed. "ADC Therapeutics’ Biologics License Application for Lonca, which was recently granted priority review status, is currently under review with the US Food and Drug Administration. As we prepare for the potential U.S. launch of Lonca in 2021, we are delighted that Overland ADCT BioPharma will expand access to the therapy, as well as three of our other pyrrolobenzodiazepine-based ADCs, to address patient needs in greater China," Chris Martin, ADC Therapeutics CEO.